References

New perspectives in management of cardiovascular risk among people with diabetes

10.1161/jaha.123.034053 · 2024 · External reference

Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes

10.1177/1479164118825376 · 2019 · External reference

10.2337/dci22-0034 · 2022 · Admitted local publication

Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association

10.1161/cir.0000000000001040 · 2022 · External reference

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes

10.1093/eurheartj/ehad192 · 2023 · External reference

Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials

10.2337/dc24-1533 · 2025 · External reference

10.2337/dc26-0298 · 2026 · Admitted local publication

Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes

10.1056/nejmoa2505928 · 2025 · External reference

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

10.1007/s00125-022-05715-4 · 2022 · External reference

Tirzepatide and cardiometabolic parameters in obesity: summary of current evidence

10.1111/dom.16549 · 2025 · External reference

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

10.1016/s0140-6736(19)31149-3 · 2019 · External reference

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1607141 · 2016 · External reference

Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

10.1056/nejmoa2108269 · 2021 · External reference

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

10.1016/s0140-6736(18)32261-x · 2018 · External reference

Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

10.2337/dc19-2251 · 2020 · External reference

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

10.1016/s0140-6736(25)01375-3 · 2025 · External reference

Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials

10.1016/j.ajpc.2024.100679 · 2024 · External reference

GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes

10.1161/circulationaha.122.059595 · 2022 · External reference

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

10.1038/s41569-023-00849-3 · 2023 · External reference

Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits

10.1172/jci194751 · 2025 · External reference

Emerging pharmacotherapies for obesity: a systematic review

10.1124/pharmrev.123.001045 · 2025 · External reference

The glitazars paradox: cardiotoxicity of the metabolically beneficial dual PPARα and PPARγ activation

10.1097/fjc.0000000000000891 · 2020 · External reference